The FDA cleared Revolution Medicines' RASONQUE on August 26, making it the first broad RAS-targeted therapy for metastatic pancreatic adenocarcinoma. The milestone caps decades of failed attempts to drug the RAS pathway, yet the stock hardly moved, shares traded around $210 on Thursday, down roughly 2% from the approval close and still within striking distance of the 52-week high of $224.31.
The data arrived months before the decision
Investors had already digested the pivotal RASolute 302 results when they were presented at oncology conferences earlier this year. That disclosure sent the stock up 41% in a single session. By the time the formal approval arrived, the market had long since priced the binary event. The subsequent consolidation near all-time highs, the stock is up more than 425% over the trailing 12 months, looks less like a "sell the news" reaction and more like a pause after an extraordinary run.
A label broader than the field expected
RASONQUE is approved for adults who have received at least one prior line of therapy, regardless of whether a RAS mutation is identified, and without a companion diagnostic. That breadth is unusual for a targeted oncology drug and reflects the platform's mechanism: a RAS(ON) tri-complex inhibitor that binds the active, GTP-bound state of the protein rather than the inactive conformation that defeated earlier programs. RAS mutations drive more than 90% of pancreatic cancers, and the pathway was long considered undruggable.
Analysts recalibrate toward what comes next
Since the approval, multiple firms have raised price targets. Evercore now sits at $320, the highest on the Street. The upward revisions suggest models already assumed approval and are now shifting toward first-line expansion, additional tumor types, and peak-sales assumptions. Technical indicators remain constructive: the 50-day moving average continues to slope higher and MACD stays in bullish territory.
Lilly looms but runs on a different timeline
Eli Lilly's olomorasib is the most cited competitive threat, yet it remains in Phase 3 and targets only the KRAS G12C subset, a single mutation subtype, with no pancreatic cancer approval to date. Lilly also has earlier-stage G12D and pan-KRAS programs, while Amgen, Roche, Merck, and Boehringer Ingelheim advance their own RAS-pathway candidates. For now, Revolution holds the only approved broad RAS inhibitor in this indication. The competitive field is real, and it will intensify.